Dr. Jeffrey Weber on Ipilimumab for Melanoma
Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.
Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.
The data were impressive, says Weber. The study showed that there was a clear benefit in terms of relapse-free survival (RFS) for the patients on the ipilimumab arm.
The median follow-up was 2.7 years, and RFS rates were 46.5% with ipilimumab versus 34.8% with placebo. The median RFS was 26.1 for ipilimumab versus 17.1 months for placebo.
Related Videos
Related Content
